This study evaluates the role of sequential therapy in HLA-haploidentical transplantation (haplo-HSCT) of high-risk, relapsed/refractory AML/MDS. We analyzed the course of 33 adults with active disease at time of transplantation (AML n = 30; MDS n = 3; median age 58 years, range: 32-71). Sequential therapy consisted of cytoreductive chemotherapy (FLAMSA n = 21; clofarabine n = 12) applied shortly prior to reduced intensity conditioning for T-cell-replete haplo-HSCT using post-transplantation cyclophosphamide as GvHD prophylaxis. No graft rejection was observed.
| INTRODUCTION
Allogeneic hematopoietic stem cell transplantation (allo-HSCT) is the only curative treatment in patients with high-risk (HR) acute myeloid leukemia (AML) who either do not achieve complete remission (CR) after induction chemotherapy, present with secondary/therapyrelated AML, develop relapsed disease, or suffer from HR myelodysplastic syndrome (MDS). [1] [2] [3] However, donor availability and thus treatment success might be limited in those patients, especially when transplanted with active disease. 2, 4, 5 Over 10 years ago, the Munich group pioneered a therapeutic concept using sequential therapy in patients affected by HR AML/MDS and refractory AML undergoing HLA-matched related or unrelated transplantation. 6, 7 It comprises an intensive cytoreductive chemotherapy applied shortly prior to reduced intensity conditioning (RIC). This salvage concept aims to improve disease control by intensified chemotherapy, thus conceding more time for the presumed graft-versus-leukemia (GvL) effect to occur. Additional donor lymphocyte infusion (DLI) is planned to further boost the latter. In sum, this sequential treatment has shown favorable outcome with long-term survival in patients with HR AML and MDS. [6] [7] [8] [9] The use of post-transplant cyclophosphamide (PTCY) for selective in vivo depletion of allo-reactive T cells [10] [11] [12] allows control of the strong bidirectional allo-reactivity observed in T-cell-replete (TCR)
haplo-HSCT. 13, 14 Following nonmyeloablative (NMA) conditioning, moderate rejection and very low graft-versus-host disease (GvHD) occurrence were observed. 12, 15 Immune reconstitution and control of infection were favorable 16, 17 resulting in astonishingly low NRM. 12, 15 Meanwhile, the outcome proved to be comparable to that of HLAmatched transplantation. [18] [19] [20] [21] Hence over time, TCR haplo-HSCT using PTCY as GvHD prophylaxis has become a valuable alternative in patients who lack a conventional donor. Nevertheless, as known from other transplantation settings, relapse remains the major challenge in haplo-HSCT, particularly when treating patients with HR disease as defined by disease risk index (DRI). 22, 23 With the intention to enhance disease control, we started to implement the concept of sequential therapy in unmanipulated haplo-HSCT utilizing a PTCY-based GvHD prophylaxis for the treatment of HR myeloid and lymphoid malignancies some years ago. 24, 25 Few data are available for this sequential haplo-HSCT, [24] [25] [26] [27] particularly when focusing on AML and MDS.
Here, we report on the outcome of the first series of patients with high-risk, relapsed or refractory (r/r) AML, and MDS undergoing sequential haplo-HSCT at our institution.
| PATIENTS AND METHODS
Patients with AML/MDS and HR profile treated with sequential TCR haplo-HSCT using PTCY for GvHD prophylaxis were enrolled. All patients lacked a suitable conventional HLA-matched donor. Five patients were included in a previous publication. 24 This monocentric, retrospective, observational study received institutional ethic committee approval, and written informed consent was obtained by all patients prior to transplantation.
Eligibility criteria comprised HR disease including r/r AML and secondary/therapy-related AML (sAML/tAML) without previous induction therapy and untreated HR MDS (EB-2 and adverse cytogenetics) 28 at the time of transplantation, ECOG ≤2, absence of uncontrolled infection, and severe organ dysfunction. Patients who had undergone a previous allo-HSCT and those in CR at the time of haplo-HSCT were considered as ineligible.
High-resolution HLA-typing (HLA-A, -B, -C, and -DRB1, -DQB1) was performed in all patients and their siblings at the time of first admission. All available parents were HLA-typed for segregation of haplotypes. Donor arrangements were completed prior to admission for sequential therapy. The decision in favor of a haploidenticalrelated donor was made if an HLA-matched donor was not available within a reasonable time frame for successful allo-HSCT as determined by disease activity. Donor-specific antibody (DSA) screening and cytotoxic cross-matching were uniformly performed. Donors were ineligible if DSA were found. Younger male, ABO-, and CMVmatched donors who were first-or higher degree relatives and shared at least one haplotype (≥5/10 but <10/10 HLA-alleles) were preferred. Degree of HLA-mismatching and results of KIR-typing/−ligand mismatching were not considered for donor choice. Selection of graft source was performed as previously described.
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| Definitions
Refractory was defined as primary induction failure (PIF) with patients not achieving CR after receiving two courses of a high-dose cytarabine containing chemotherapy or relapse refractory to salvage treatment. The redefined DRI was used for evaluation of disease risk. , and amsacrine 100 mg/m 2 IV over 4 days) or clofarabine (30 mg/m 2 IV over 5 days) as described previously. 7, 24 Clofarabine was preferred in patients who underwent several courses of cytarabine-based therapy before showing r/r disease. After 3 days of rest, conditioning was started in aplasia without further assessment of disease status. Conditioning was TBI-based in patients <60 years and drug-based in the elderly. Postgrafting immunosuppression with high-dose cyclophosphamide (CY) (50 mg/kg IV on day +3 and +4) was combined to mycophenolate mofetil (MMF) and tacrolimus (Tac) initiated at day +5, as reported earlier. 12 MMF was stopped on day +35. Tac was tapered starting from day +140. G-CSF was routinely administered starting on day +5 until neutrophil engraftment (Supporting Information, Figure 1 ). In the absence of history or evidence of GvHD of any grade, prophylactic DLI (pDLI) was possible after discontinuation of immunosuppression.
| Supportive care
Supportive care consisted of standard antimicrobial prophylaxis including micafungin or liposomal amphotericin B and infection surveillance according to local center strategies. 17 Hyperhydration and
Mesna were continuously co-infused for prophylaxis of hemorrhagic cystitis (HC) on days of CY application. Ursodeoxychol acid and unfractionated low-dose heparin were applied for VOD prophylaxis.
| Statistical methods
Patients were assessed for overall survival (OS), disease-free survival (DFS), GvHD-free and relapse-free survival (GRFS), and for chronic
GvHD-free and relapse-free survival (CRFS). GRFS and CRFS were defined as previously described. 21 Relapse was defined as hematological relapse. Event time distributions were measured from date of haplo-HSCT. OS, DFS, GRFS, and CRFS were estimated using the KaplanMeier method. 33 Univariate comparisons were made using the log-rank test. Probability of NRM was estimated by competing risk analysis with relapse as competitive risk and vice versa. Cumulative incidence (CI) of GvHD was estimated using relapse and death from any other cause as competing risk. 34 Comparisons between CI curves were performed using the Gray test. 35 Toxicity variables were compared between two groups using the Chi-square statistics or Fisher's exact test for categorical variables. All statistical tests were two-sided and a P value of <.05 was considered statistically significant. Data were analyzed using R 3.2.0 statistical software (http://www.R-project.org).
| RESULTS
Details on patient-, donor-, and transplant characteristics are given in Table 1 . Sequential haplo-HSCT was offered to 33 patients with AML (n = 30) and MDS (n = 3) at a median age of 58 years (range: 32-71).
Disease status at time of sequential therapy included 18 patients in first
relapse ( Table 1 .
| Engraftment and rejection
No primary graft rejection occurred. 
| GvHD
CI of acute GvHD (aGvHD) grade II-IV was 24% (95% CI: 22-26) (Supporting Information, Table 2 ). Grade I-II aGvHD solely involved the skin and affected 23/29 patients. Only one patient developed grade III aGvHD involving skin and gut. No grade IV aGvHD was observed, resulting in a CI of severe aGvHD (III-IV ) of 3% (95% CI: 1-5).
CI of chronic GvHD (cGvHD) was 38% (95% CI: 35-41) with a CI of severe cGvHD of 3.7% (95% CI: 2-6) at one-year post haplo-HSCT with only one noted case of severe cGvHD involving skin and lung (Supporting Information, Table 2 ). All but two cases of chronic GvHD resolved within the observation period under immunosuppressive treatment. No patient died due to GvHD. Rates of acute and chronic GvHD are given in Supporting Information, Table 1 .
While no significant difference in CI of cGvHD at 1 year was seen when comparing the utilized graft source (BM CI cGvHD 20% vs PBSCs CI cGvHD 50%; P = .09), there was a significantly higher incidence of aGvHD (any grade) after sequential haplo-HSCT using PBSCs (BM CI aGvHD 35% vs PBSCs CI aGvHD 80%; P = .005). The risk of grade II-IV aGvHD showed a trend toward higher incidence in the PBSC group (BM aGvHD II-IV 7% vs PBSCs CI aGvHD II-IV 35%; P = .06).
| Treatment-related toxicities and infections
Cytoreductive chemotherapy and RIC was well tolerated. No patient died prior to transplantation. Severe nonhematological regimen-related toxicities (grade III-IV) occurred in 19/33 patients (58%) and are summarized in Table 2 . Two patients suffered from ≥2 grade III-IV toxicities.
Higher grade diarrhea occurred in 16/33 patients (grade IV: n = 2) frequently starting soon after conditioning, deteriorating after PTCY appli- 
| Nonrelapse mortality
The day +100, 1-year, and 3-year CI of NRM were 9%, 15%, and 15%, respectively ( Figure 1 , Supporting Information, Table 2 ). Causes of death are specified in Supporting Information, Table 4 . Four patients died in early aplasia (n = 3 infection, n = 1 cardiac failure). Infection was the leading cause of death (sole n = 4; with contribution n = 1).
Lethal infections included invasive fungal (aspergillosis, Fusarium sepsis, Pichia caribbica sepsis) and bacterial (Pseudomonas putida sepsis).
3.5 | Disease response, relapse, and donor lymphocyte infusion CR was achieved in 28/29 evaluable patients (97%) by day +30, while early disease progression at day +20 was assessed in one patient.
The 1-year, 2-year, and 3-year CI of relapse were 28%, 35%, and 35%, respectively (Figure 1 , Supporting Information, Table 2 ). Thirteen patients relapsed at a median of 5 months (0.7-33 months) after haplo-HSCT; thereof 11 patients relapsed within the first year after haplo-HSCT. Median OS for relapsed patients was 6 months (0-12 months). Occurrence of aGvHD (I-IV ) showed a trend toward lower relapse incidence at 1 year (no aGvHD 43% vs any aGvHD 18%; P = .07) in univariate testing.
No patient was able to receive intended pDLI, because of either early death (n = 10), history of GvHD (n = 14), occurrence of GvHD after discontinuation of postgrafting immunosuppression (n = 8), or recurrent infection (n = 1).
| Survival
Survival data and curves are shown in Figure 1 and Supporting Information, Table 2 . At a median follow-up of 36 months (range: 17-77) among survivors, 1-and 2-year OS was 56% (95% CI: 53-59) and 48% Table 2 ). Patients with aGvHD of any grade showed a 1-year overall survival benefit (74% vs 14%; P < .0001) (Supporting Information, Table 3 ).
Estimates for 1-, 2-, and 3-year DFS were 49% (95% CI: 46-52), 46% (95% CI: [43] [44] [45] [46] [47] [48] [49] , and 40% (95% CI: 37-43), respectively. Out of six patients who did not develop aGvHD, five died due to early relapse within the first year (1-year DFS: 70% vs 0%; P < .0001) (Supporting Information, Table 3 ). All other factors tested, particularly cGvHD, had no impact on outcome parameters (Supporting Information, Table 3 ).
GRFS at 1-year was 24% (95% CI: 22-26). After 9 months, no further event occurred, resulting in a 2-and 3-year GRFS of 24% (95% CI:
22-26), both. Distribution of first event components is illustrated in Figure 1C . While NRM (n = 6) and relapse (n = 8) made up a similar proportion of first GRFS events, severe, grade III acute GvHD was seen in one patient only. For chronic GvHD requiring immunosuppression, 10 events were recorded: four mild, five moderate, and one severe chronic GvHD. Accordingly, 1-, 2-, and 3-year estimates for CRFS were 36% (95% CI: 33-39), 33% (95% CI: 30-36), and 29% (95% CI: 26-32), respectively (Supporting Information, Table 2 ). Distribution of overall first events is shown in Figure 1C and appears similarly to GRFS-first event distribution while less chronic GvHD is seen.
| DISCUSSION
Disease control remains of major concern when treating patients suffering from HR myeloid malignancies such as r/r AML, sAML/tAML, and HR MDS with haplo-HSCT using PTCY. 12, 15, 16, 18, 23 In earlier studies based on NMA conditioning high relapse incidences and thus limited survival were reported, especially for patients with active disease at time of transplantation. 12, 15, 18, 23 Intensification of conditioning (MAC) seems to result in better disease control with acceptable NRM in this transplantation setting. 18, [36] [37] [38] However, in patients transplanted with Abbreviations: ARF, acute renal failure; FLAMSA, chemotherapy regimen consisting of fludarabine, cytarabine, and amsacrin; HC, hemorrhagic cystitis.
FIGURE 1 A, Kaplan-Meier curves of overall survival (OS), disease-free survival (DFS), and cumulative incidences (CI) of NRM and relapse. B, Kaplan-Meier curves of GvHD-and relapse-free survival (GRFS) and chronic GvHD-and relapse-free survival (CRFS). C, Distribution of first event components of GRFS and CRFS. Abbreviations: NRM, nonrelapse mortality; aGvHD, acute graft-versus-host disease; cGvHD, chronic graft versus-host disease aggressive, active myeloid disease there is still room for improvement. 19, 26, 39 As such, novel strategies are needed to make TCR haplo-HSCT a valuable alternative in case a conventional donor is lacking.
Here, we show that a sequential therapy concept combining an intensive cytoreductive chemotherapy shortly prior to an RIC-based haplo-HSCT using PTCY for GvHD prophylaxis is a promising approach in patients with HR AML/MDS and active disease at time of transplantation, leading to a high anti-leukemic activity, remarkable tolerance, and a favorable long-term outcome. With a low incidence of severe GvHD, an acceptable toxicity profile and reasonable disease control our results are at least comparable to the ones observed in earlier studies in a sequential HLA-matched transplantation setting for HR AML/MDS using ATG for in vivo T-cell depletion. 6, 7 So far, we have learned that integrating a sequential therapy concept in haplo-HSCT is easy to perform in patients affected by HR malignancies, 24, 25 most likely due to the favorable safety profile of the underlying haplo-HSCT platform using PTCY. 12, 15, 16 Severe toxicities including mucositis, nausea, and diarrhea were manageable by carefully guided supportive care in our cohort. Recapped, we did not observe any remarkable differences in the development of toxicities when comparing the two different cytoreductive regimens used.
However, due to unlimited availability and the widespread clinical use in AML, we suggest the use of FLAMSA with a TBI-based (4 Gy) conditioning in younger and drug-based (melphalan) conditioning in elderly patients.
To mitigate early infections while treating HR AML/MDS, the use of PBSCs instead of BM might appear advantageous by anticipating a favorable neutrophil engraftment. However, in TCR haplo-HSCT, this might be counterbalanced by a higher incidence of severe aGvHD contributing to remarkable morbidity in those patients. 40, 41 In our cohort, we observed significantly more aGvHD after transplantation of PBSCs while time to engraftment and thus duration of neutropenia was similar among the two groups. Therefore, we suggest that the problem of frequently seen IFIs in our cohort-accounting for most NRM events-rather seems to be attributable to the underlying disease, pre-existing neutropenia and prior history of fungal infection than of the entire strategy.
Although in AML it has been shown that using MAC instead of RIC in PTCY haplo-HSCT leads to a significant lower risk of relapse without increasing NRM, 18 there is suboptimal disease control considering that DFS ranges from 10% to 32% in patients haplo-grafted with nonremission AML. 19, 26, 38, 39, 42 Using a sequential therapy concept in those patients might be a promising approach. Recently, Dulery et al. reported on the outcome of 17 refractory AML patients treated with a cytoreductive chemotherapy followed by an intensified conditioning for TCR haplo-HSCT. While feasibility was shown, outcome proved to be worse when compared to our sequential haplo-cohort.
Furthermore, the median follow-up for this haplo-cohort was short, thus not allowing any outlook on long-term outcome. 27 Interestingly, in this retrospective analysis, it has been speculated that addition of low-dose ATG to a PTCY-based GvHD prophylaxis might further decrease the incidence of GvHD in sequential haplo-HSCT, particularly when PBSCs are used as graft source. 27 However, when comparing the results of this French/Italian multicenter study including patients with various hematological diseases to our exclusively PTCYbased approach in HR AML/MDS patients, our approach seems to be at least equally effective in reducing severe GvHD although we 25, 47, 48 Taking that into consideration, attenuating safety criteria for the application of pDLI might lead to a slight increase of the numbers of patients who are able to undergo this relapse prevention strategy. Nevertheless, considering our data, pDLI application by day +210 might be too late to strengthen the GvL-effect.
Recently, Kasamon et al. reported on the safety of early cessation of postgrafting immunosuppression in the TCR haplo-setting using PTCY for GvHD prophylaxis. If using this safe platform, 49 we might get in the favorable position to apply pDLI earlier in the course after haplo-HSCT. However, their experience is not so easy to translate into ours in patients with high-risk, r/r AML/MDS: BM was the only graft source used, whereas we used PBSCs in~50% of the cases which is associated with a higher GvHD incidence per se in TCR haplo-HSCT. 40, 41 They further showed that patients with grade I aGvHD experiencing early tapering of immunosuppressants developed higher grade GvHD, which would exclude them from further post-transplantation immunotherapies. We speculate that early cessation of immunosuppression might be a valuable tool for the subset of patients without history of aGvHD to trigger the latter, as mild aGvHD occurrence might protect from relapse. 44 Another approach favors the early application of prophylactic G-CSF stimulatedmobilized DLIs after MAC conditioning in PTCY-based haplo-HSCT during ongoing postgrafting immunosuppression. 50 Here, compared groups were small, heterogeneous, and improved disease control was achieved at a dispense of remarkably more cGvHD. 50 However, after all, survival of our patient cohort compares favorably to others, even without application of pDLI. This might be due to the unique immunomodulatory potential of PTCY application itself in the haplosetting, 10, 11 where it promotes mild GvHD while preventing severe GvHD which translates in improved DFS.
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The small sample size, the retrospective nature, and the lack of a comparative arm and center effects might hamper this analysis. However, this study is the first to report the outcome in a series of sequential haplo-HSCT using PTCY for GvHD prophylaxis in HR AML/MDS.
In summary, we suggest that utilizing sequential therapy in TCR/PTCY haplo-HSCT is safe and effective in the treatment of HR AML/MDS. Especially in this group of patients lacking a conventional donor, our sequential haplo-HSCT approach using an exclusively PTCY-based GvHD prophylaxis seems to offer long-term disease control.
We anticipate that by avoiding delays between induction and transplantation, sequential haplo-HSCT may result in more patients successfully undergoing this potentially life-saving procedure, overall shortening the total duration of the treatment.
